Global Statistics

All countries
137,252,621
Confirmed
Updated on April 12, 2021 9:32 pm
All countries
110,410,583
Recovered
Updated on April 12, 2021 9:32 pm
All countries
2,958,629
Deaths
Updated on April 12, 2021 9:32 pm
Monday, April 12, 2021

Global Statistics

All countries
137,252,621
Confirmed
Updated on April 12, 2021 9:32 pm
All countries
110,410,583
Recovered
Updated on April 12, 2021 9:32 pm
All countries
2,958,629
Deaths
Updated on April 12, 2021 9:32 pm
Molderizer and Safe Shield

Coronavirus treatment highly effective in reducing, shortening symptoms

What you need to know about getting a COVID-19 vaccine in the north metro, following the police killing of Daunte Wright.

Vaccine appointments will be delayed in at least two locations in the north metro. following Sunday afternoon’s police killing of Daunte Wright in...

Trump Invokes Defense Production Act To Make 'Important' Coronavirus Supplies | NBC News

NBC News Digital is a collection of innovative and powerful news brands that deliver compelling, diverse and engaging news stories. NBC News Digital features...

Vaccine Update: Who's leading in creating an effective coronavirus vaccine? | DW News

News last week of a promising coronavirus vaccine candidate from Pfizer and German firm BioNTech prompted ecstatic headlines. The vaccine was developed ... source

UK Eases Its Coronavirus Lockdown, and Britons Rejoice

LONDON — In China it was fengcheng. In Spain it was el confinamiento. In France it was le confinement. In Britain it was...

[Full text] Practices of Medical students toward COVID-19

Introduction In late December 2019, a number of cases of pneumonia-like disease caused by a new coronavirus were reported in Wuhan, China.1 It was...


EAST GREENBUSH – The “antibody cocktail” being developed by Regeneron Pharmaceuticals has proven highly effective in reducing and shortening COVID-19 symptoms, according to test results announced by the company this week.

The cocktail worked well in low, moderate and high doses and Regeneron said it would request approval to move forward with the lower dose, which should allow for more production.

Regeneron’s Regen-Cov treatment made headlines last fall when it was given to former President Donald J. Trump who contracted but quickly recovered from COVID-19. The treatment has been permitted under an emergency provision to help fight the pandemic.

In the latest clinical trial results, Regen-Cov antibody cocktail reduced hospitalizations or death by 70 percent among COVID-19 patients. It also shortened the duration of virus symptoms by four days.

Based in Tarrytown, Westchester County, Regeneron has a significant presence in the Capital Region with a major operations and product supply center in Rensselaer County, employing  3,000 people. The center manufactured the COVID treatment given the former president.

Coronavirus resources

Detailed map: Check out the Times Union’s New York Coronavirus Case Tracker.

Testing: Local testing sites for COVID-19. Coronavirus testing results for every New York county.

Vaccinations: Track vaccine roll-out in New York. Plus, get answers to commons questions and submit your own here.

Lives lost: Share a remembrance of a Capital Region resident who died from COVID-19.

Daily email: Sign up for the free Coronavirus Updates newsletter.


Regeneron is also expanding into a new $800 million manufacturing complex on 130 acres off Tempel Lane in East Greenbush, near its main plant near Columbia Turnpike.


They have said they plan to employ more than 4,000 people in the Capital Region by the end of 2024.

Unlike the mRNA vaccines currently being distributed by Pfizer and Moderna, Regen-Cov is not preventive. But it appears to significantly reduce symptoms and duration for those infected with the virus, tests show.

The cocktail combines two man-made antibodies, Casirvimab and Imdevimab. Doses ranging from 8,000 to 2,400 to 1,200 milligrams seemed to work as well as one another.

Regeneron has said they could produce about 750,000 doses by the summer, based on the 2,400-milligram level. But if approved at the lower dose, they could produce more, the company has said.

“We will discuss the new data with regulatory authorities and request that the 1,200 mg dose be rapidly added to the U.S. Emergency Use Authorization, in order for the anticipated REGEN-COV supply to be available to treat even more patients, said Dr. George D. Yancopoulos, President and Chief Scientific Officer at Regeneron

“This is a landmark moment in the fight against COVID-19 as this large well-controlled trial provides conclusive results demonstrating that REGEN-COV can dramatically reduce the risk of hospitalization and death in the outpatient setting,” said Suraj Saggar, D.O., trial investigator and Chief of Infectious Disease at Holy Name Medical Center in Teaneck, New Jersey. “With so many people still getting infected, as well as recent data showing that REGEN-COV addresses emerging variants, these data underscore the need to rapidly adopt REGEN-COV as standard-of-care to offer high-risk patients their best chance to reduce serious consequences like hospitalization or death.”

There are currently three vaccines being distributed to the public – from Pfizer, Moderna and Johnson & Johnson. Pfizer and Moderna use mRNA technology.

Rather than introducing a shortened or attenuated version of the virus to stimulate an immune response, mRNA or messenger RNA, provides genetic instructions to the body’s immune cells to react to the COVID-19 virus.

Regneron’s stock opened at $486.16 on the NASDAQ exchange Tuesday morning, up from a 52-week low of $424.01, with a high of $488.72.

rkarlin@timesunion.com 518 454 5758 @RickKarlinTU



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Popular

What you need to know about getting a COVID-19 vaccine in the north metro, following the police killing of Daunte Wright.

Vaccine appointments will be delayed in at least two locations in the north metro. following Sunday afternoon’s police killing of Daunte Wright in...

Trump Invokes Defense Production Act To Make 'Important' Coronavirus Supplies | NBC News

NBC News Digital is a collection of innovative and powerful news brands that deliver compelling, diverse and engaging news stories. NBC News Digital features...

Vaccine Update: Who's leading in creating an effective coronavirus vaccine? | DW News

News last week of a promising coronavirus vaccine candidate from Pfizer and German firm BioNTech prompted ecstatic headlines. The vaccine was developed ... source

Related Articles

What you need to know about getting a COVID-19 vaccine in the north metro, following the police killing of Daunte Wright.

Vaccine appointments will be delayed in at least two locations in the north metro. following Sunday afternoon’s police killing of Daunte Wright in...

Trump Invokes Defense Production Act To Make 'Important' Coronavirus Supplies | NBC News

NBC News Digital is a collection of innovative and powerful news brands that deliver compelling, diverse and engaging news stories. NBC News Digital features...

Vaccine Update: Who's leading in creating an effective coronavirus vaccine? | DW News

News last week of a promising coronavirus vaccine candidate from Pfizer and German firm BioNTech prompted ecstatic headlines. The vaccine was developed ... source